Embecta Corp.

Embecta Corp. is a U.S.-based diabetes care company spun out of BD in 2022 that sells injection devices used to deliver insulin and other diabetes therapies. Its core business is a global portfolio of pen needles, syringes, and safety injection devices sold through distributors, retail pharmacies, hospitals, and other healthcare channels in more than 100 countries.

26,2 %

62,6 %

8,8 %

−3,8 %

2.41

1.73

— Embecta Corp.
%
Pen needles55% Sterile, single-use needles used with pen injectors to deliver insulin and other diabetes drugs.
Safety pen needles20% Needles with protective shields designed to reduce needlestick exposure during injection and disposal.
Syringes15% Traditional diabetes syringes used for injectable therapy and related administration needs.
Safety injection devices and accessories10% Other injection-related products supporting safe and convenient diabetes drug administration.

Embecta sells primarily into the diabetes care ecosystem, where demand is driven by patients using insulin or other...

  • Wholesale distributorsprimary

    Cencora, McKesson, Cardinal Health and similar distributors buy in bulk and resell into pharmacy and healthcare channels.

  • Retail pharmaciesprimary

    Large pharmacy chains and independent pharmacies buy Embecta products for direct sale to diabetes patients.

  • Hospitals and institutional buyerssecondary

    Hospitals and other institutions buy injection devices for clinical use and patient discharge needs.

  • End users with diabetesprimary

    Patients ultimately use the products for insulin and other injectable diabetes therapies, driving repeat demand.

  • Healthcare professionalssecondary

    Physicians and diabetes care professionals influence product adoption, training, and therapy administration choices.

Embecta operates a global manufacturing and distribution network and sells into more than 100 countries...

  • •Sales and distribution in over 100 countries
  • •Manufacturing sites in Ireland, the United States, and China
  • •Global commercial reach through retail, hospitals, and pharmacies
  • •International operations expose the company to tariffs and trade barriers
  • •Brand and license transfers across countries remain operationally important

Embecta’s strategy is centered on protecting its core diabetes injection franchise while improving operational...

01
Brand transition and license transfershort-term

Embecta must rebrand products and transfer registrations to avoid commercialization disruptions.

02
Operational independence from BDshort-term

The company needs to replace transition services and business continuity processes to run as a standalone public company.

03
Portfolio expansion through partnerships and M&Amedium-term

New technologies and complementary products could reduce dependence on legacy injection devices and open new markets.

04
Patch pump and product development initiativesmedium-term

New diabetes delivery technologies are needed to defend against competitive and therapeutic shifts.

Embecta is exposed to concentrated customer and product risk because a few distributors and a small number of core...

high

Customer concentration

A few distributors account for a large share of worldwide gross sales, so pricing or volume changes can quickly affect revenue.

Scope
Cencora, McKesson, Cardinal Health and major retail pharmacies
Materiality
high
high

Dependence on core products

The company generates significant profits and cash flow from a limited set of diabetes injection products.

Scope
Pen needles, syringes, safety devices
Materiality
high
high

Separation and rebranding execution

Failure to transfer licenses, registrations, and product branding could interrupt commercialization and distribution.

Scope
BD transition, regulatory registrations, supply chain systems
Materiality
high
high

Leverage and refinancing risk

Large debt obligations consume cash flow and may limit future borrowing or dividend capacity.

Scope
Term loan and notes outstanding
Materiality
high
medium

Competitive and technology disruption

New drug therapies, pumps, and injection technologies can reduce demand for legacy devices.

Scope
Diabetes care market
Materiality
high
Separation and restructuring charges
Operating income and cash flow
Revenue timing through distributors
Revenue and gross margin
Lease accounting
Operating expenses and liabilities
Debt and interest accounting
Net income, cash flow, and leverage metrics
Impairment and intangible assets
Earnings and asset values

INSULET CORP

PODD · Surgical & Medical Instruments & Apparatus

TANDEM DIABETES CARE INC

TNDM · Surgical & Medical Instruments & Apparatus

FRACTYL HEALTH, INC.

GUTS · Surgical & Medical Instruments & Apparatus

ENANTA PHARMACEUTICALS INC

ENTA · Pharmaceutical Preparations

Beta Bionics, Inc.

BBNX · Surgical & Medical Instruments & Apparatus

Medtronic plc

MDT · Electromedical & Electrotherapeutic Apparatus

: 28/04/2026